These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 8382857)

  • 1. Acquired selective immunoglobulin A deficiency in renal transplant recipients.
    Chevet D; Rifle G; Guiguet M; Chalopin JM; Tanter Y; Mousson C; Rebibou JM
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1355-8. PubMed ID: 8382857
    [No Abstract]   [Full Text] [Related]  

  • 2. Renal transplantation in selective IgA deficiency.
    Ueda H; Kanoh T; Ohara H; Itoh S; Matsuo Y; Isurugi K
    Nihon Jinzo Gakkai Shi; 1994 Jan; 36(1):76-9. PubMed ID: 8107313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal immunosuppressive regimen for hepatitis B-positive kidney transplant recipients.
    Hsieh H; Chen CH; Huang HF; Tseng YJ
    Transplant Proc; 1996 Jun; 28(3):1495-7. PubMed ID: 8658757
    [No Abstract]   [Full Text] [Related]  

  • 4. Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease.
    Conti DJ; Freed BM; Lempert N
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1421-2. PubMed ID: 8382867
    [No Abstract]   [Full Text] [Related]  

  • 5. The fate of glomerular mesangial IgA deposition in the donated kidney after allograft transplantation.
    Ji S; Liu M; Chen J; Yin L; Sha G; Chen H; Liu Z; Li L
    Clin Transplant; 2004 Oct; 18(5):536-40. PubMed ID: 15344956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HBsAg as predictor of outcome in renal transplant patients.
    Ridruejo E; Brunet Mdel R; Cusumano A; Diaz C; Michel MD; Jost L; Jost L; Mando OG; Vilches A
    Medicina (B Aires); 2004; 64(5):429-32. PubMed ID: 15560544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience.
    Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J
    Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of kidney transplantation in Krakow in 1992-2000].
    Kuzniewski M; Ignacak E; Bucki J; Czupryna A; Prokop A; Pituch-Noworolska A; Hajto B; Zawilińska B; Skuciński J; Giza D; Popiela T; Zembala M; Sułowicz W
    Przegl Lek; 2000; 57(11):619-23. PubMed ID: 11293208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of chronic allograft nephropathy and subsequent modifications of immunosuppressive therapy on late graft outcomes in renal transplantation.
    Montagnino G; Banfi G; Campise MR; Passerini P; Aroldi A; Cesana BM; Ponticelli C
    Nephrol Dial Transplant; 2004 Oct; 19(10):2622-9. PubMed ID: 15316096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
    So S; Mayo C; McCullough C; Jendrisak M; Woodle S; Marsh W; Bailey T
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865
    [No Abstract]   [Full Text] [Related]  

  • 11. Human cytomegalovirus specific CD8(+) T lymphocytes display interferon-gamma secretion impairment in kidney transplant recipients with pp65 antigenemia.
    Yang R; Xia T; Xu G; Li Z; Ying Z; Xu X
    Transplant Proc; 2008 Dec; 40(10):3500-4. PubMed ID: 19100424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganciclovir in cytomegalovirus prophylaxis in high-risk pediatric renal transplant recipients.
    Prokurat S; Drabik E; Grenda R; Vogt E
    Transplant Proc; 1993 Aug; 25(4):2577. PubMed ID: 8395104
    [No Abstract]   [Full Text] [Related]  

  • 13. Renal transplantation in cyclosporine-treated recipients at the Singapore General Hospital.
    Vathsala A; Woo KT
    Clin Transpl; 1999; ():189-97. PubMed ID: 11038637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryoglobulinemia in kidney transplant recipients.
    Sens YA; Malafronte P; Souza JF; Bruno S; Gonzalez RB; Miorin LA; Jabur P; Forte WC
    Transplant Proc; 2005 Dec; 37(10):4273-5. PubMed ID: 16387095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival.
    McLaughlin K; Sandhu S; Wu C; Muirhead N; Hollomby D; Jevnikar A
    Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latent IgA deposition from donor kidney is the major risk factor for recurrent IgA nephropathy in renal transplantation.
    Moriyama T; Nitta K; Suzuki K; Honda K; Horita S; Uchida K; Yumura W; Tanabe K; Toma H; Nihei H; Yamaguchi Y
    Clin Transplant; 2005; 19 Suppl 14():41-8. PubMed ID: 15955168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent anemia in kidney transplant recipients with parvovirus B19 infection.
    Renoult E; Bachelet C; Krier-Coudert MJ; Diarrassouba A; André JL; Kessler M
    Transplant Proc; 2006 Sep; 38(7):2321-3. PubMed ID: 16980079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of presence of HBs antigen and anti-hepatitis C virus and anti-cytomegalovirus antibodies on transplanted kidney survival.
    Sieńko J; Wiśniewska M; Ciechanowski K; Rózański J; Domański L; Myslak M; Kamiński M; Sulikowski T; Pabisiak K; Romanowski M; Mizerski A; Tejchman K; Nowacki M; Ostrowski M; Bohatyrewicz R
    Transplant Proc; 2006; 38(1):136-8. PubMed ID: 16504685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss.
    Rodríguez LM; París SC; Arbeláez M; Cotes JM; Süsal C; Torres Y; García LF
    Hum Immunol; 2007 Aug; 68(8):652-60. PubMed ID: 17678719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.